The company reveals the first overall survival data in adjuvant ER-positive breast cancer.

Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.

A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.

The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

But more detail is awaited, especially on toxicity.